HDAC9 and Miyoshi myopathy: These results are very similar to those obtained when testing combinations of IMiDs with ACY-1215 (S2B Fig), confirming broad synergy of these selective HDAC inhibitors with the IMiD class of drugs in MM cell lines, and suggesting activity in other B-cell malignancies where IMiDs are active, such as MCL.